Turner Heather D
SEC-identified person · CIK 1403571 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Terns Pharmaceuticals, Inc. TERN | Director | filed 2024–2026 |
| Avalyn Pharma Inc. AVLN | Director | filed 2026–2026 |
| LB Pharmaceuticals INC LBRX | Director · Chief Executive Officer | filed 2025–2025 |
| Lyell Immunopharma, Inc. LYEL | Chief General Counsel | filed 2021–2022 |
| Sangamo Therapeutics, INC SGMO | SVP and General Counsel | filed 2018–2019 |
| Atara Biotherapeutics, Inc. ATRA | VP, General Counsel & Sec. | filed 2015–2018 |
| Orexigen Therapeutics, Inc. OREXQ | Vice President | filed 2007–2015 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.